Table 1.

Patient Characteristics.

		CPB Arm (A) N=75	CPBE Arm (B) N=73	Combined	p-value
Age					0.62
	Median	59	58	59
Gender					0.03
	Female	21 (28.0%)	33 (45.2%)	54 (36.5%)
	Male	54 (72.0%)	40 (54.8%)	94 (63.5%)
Race					0.22
	White	74 (98.7%)	71 (97.3%)	145 (98.0%)
	Black	1 (1.3%)	0 (0.0%)	1 (0.7%)
Primary Site					0.32
	Head	2 (2.7%)	7 (9.7%)	9 (6.2%)
	Neck	1 (1.4%)	2 (2.8%)	3 (2.1%)
	Upper Extremity	6 (8.1%)	8 (11.1%)	14 (9.6%)
	Lower Extremity	17 (23.0%)	9 (12.5%)	26 (17.8%)
	Trunk	15 (20.3%)	19 (26.4%)	34 (23.3%)
	Uveal	16 (21.6%)	10 (13.9%)	26 (17.8%)
	Mucosal	1 (1.4%)	1 (1.4%)	2 (1.4%)
	Anogenital	2 (2.7%)	0 (0.0%)	2 (1.4%)
M stage					0.35
	M1a	9 (12.0%)	4 (5.5%)	13 (8.8%)
	M1b	11 (14.6%)	12 (16.4%)	23 (15.5%)
	M1c	56 (74.7%)	57 (78.1%)	113 (76.4%)
Prior Chemotherapy					0.6
	Yes	16 (21.6%)	15 (20.5%)	31 (21.1%)
	No	58 (78.4%)	57 (78.1%)	115 (78.2%)
Prior Immunotherapy					0.46
	Yes	26 (35.1%)	30 (41.1%)	56 (38.1%)
	No	48 (64.9%)	43 (58.9%)	91 (61.9%)
Prior Angiogenesis Therapy					0.31
	Yes	74 (100%)	72 (98.6%)	146 (99.3%)
	No	0 (0%)	1 (1.4%)	1 (0.7%)
Prior Ipilimumab					0.61
	Yes	12 (16.0%)	14 (19.2%)	26 (17.6%)
	No	63 (84.0%)	59 (80.8%)	122 (82.4%)
Prior BRAF inhibitor					0.67
	Yes	3 (4.0%)	4 (5.5%)	7 (4.7%)
	No	72 (96.0%)	69 (94.5%)	142 (95.9%)
LDH Elevated					0.48
	Yes	36 (48%)	38 (73%)	74 (50%)
BRAF					0.71
	Wildtype	41 (77.4%)	38 (56.7%)	79 (74.5%)
	Mutated	12 (22.6%)	15 (48.3%)	27 (25.4%)
C-kit					0.59
	Wildtype	9 (90.0%)	10 (100%)	19 (95.5%)
	Mutated	1 (10.0%)	0 (0%)	1 (5.0%)

CPB (Carboplatin, Paclitaxel, Bevacizumab), CPBE (Carboplatin, Paclitaxel, Bevacizumab, Everolimus)